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HLAclassI-associatedpolymorphismsidentiﬁedatthepopulationlevelmarkviralsitesunderimmunepressurebyindividual
HLAalleles.Assuch,analysisoftheirdistribution,frequency,location,statisticalstrength,sequenceconservation,andother
propertiesoffersauniqueperspectivefromwhichtoidentifycorrelatesofprotectivecellularimmunity.WeanalyzedHLA-asso-
ciatedHIV-1subtypeBpolymorphismsin1,888treatment-naïve,chronicallyinfectedindividualsusingphylogeneticallyin-
formedmethodsandidentiﬁedcharacteristicsofHLA-associatedimmunepressuresthatdifferentiateprotectiveandnonprotec-
tivealleles.Over2,100HLA-associatedHIV-1polymorphismswereidentiﬁed,approximatelyone-thirdofwhichoccurredinside
orwithin3residuesofanoptimallydeﬁnedcytotoxicT-lymphocyte(CTL)epitope.DifferentialCTLescapepatternsbetween
closelyrelatedHLAalleleswerecommonandincreasedwithgreaterevolutionarydistancebetweenallelegroupmembers.
Among9-merepitopes,mutationsatHLA-speciﬁcanchorresiduesrepresentedthemostfrequentlydetectedescapetype:these
occurrednearly2-foldmorefrequentlythanexpectedbychanceandwerecomputationallypredictedtoreducepeptide-HLA
bindingnearly10-foldonaverage.CharacteristicsassociatedwithprotectiveHLAalleles(deﬁnedusinghazardratiosforpro-
gressiontoAIDSfromnaturalhistorycohorts)includedthepotentialtomountbroadimmuneselectionpressuresacrossall
HIV-1proteinsexceptNef,thetendencytodrivemultisiteand/oranchorresidueescapemutationswithinknownCTLepitopes,
andtheabilitytostronglyselectmutationsinconservedregionswithinHIV’sstructuralandfunctionalproteins.Thus,thefac-
torsdeﬁningprotectivecellularimmuneresponsesmaybemorecomplexthansimplytargetingconservedviralregions.The
resultsprovidenewinformationtoguidevaccinedesignandimmunogenicitystudies.
H
IV-1 is notorious for its genetic diversity and its ability to
adapt to selection pressures (44, 87, 116). Despite this, with-
in-host HIV-1 evolution in response to antiretroviral (61, 72),
host cellular immune (15, 50, 71, 94, 95), antibody (46), and vac-
cine-induced(103)selectionpressuresoccursalonggenerallypre-
dictablemutationalpathways(3,84).Studyingtheseevolutionary
pathways can offer insight into the immunopathogenesis of
HIV-1 and may help inform the design of immune-based inter-
ventions and vaccines.
Substantial progress has been made in our understanding of
HIV-1’s ability to evade human leukocyte antigen (HLA) class
I-restricted CD8
 cytotoxic T-lymphocytes (CTL). In particular,
application of novel statistical methods (13, 25, 84) to large pop-
ulation-based data sets of linked host and viral genetic informa-
tionhasfacilitatedthesystematicidentiﬁcationofHLA-associated
immuneescapeandcovaryingmutationsinHIV-1(19,20,60,81,
99,104),revealingimportantinsightsintoHIV-1adaptationtoits
host. We now appreciate that immune selection represents a ma-
jorforceshapingHIV-1diversity(3,80,84)andthatHIV-1escape
pathways are generally predictable in the context of host HLA
allele expression (3, 19, 84). Immune escape mutations occur
within and outside CTL epitopes (13, 20, 60, 99, 104) and can
compromise peptide-HLA binding (8, 65), disrupt intracellular
antigen processing (35, 122), affect T-cell recognition of the pep-
tide-HLA complex (23, 58, 59, 96, 117), and/or potentially affect
killer immunoglobulin-like receptor (KIR) binding (16, 113).
WhilesomeescapepathwaysarelikelytobeuniversalacrossHLA
alleles and/or HIV-1 subtypes, widespread examples of differen-
tial escape between infected populations (9, 60) and between
closely related HLA class I alleles (26, 69, 86) have also been dem-
onstrated. Population-level studies have also allowed us to esti-
mate rates (18) and clinical implications (21, 81) of immune es-
cape, infer ﬁtness costs of speciﬁc mutations (81), discover novel
epitopes in conventional (5, 13) and cryptic (10, 12) reading
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 frames,andforecasttheconsequencesofcontinuedimmune-me-
diated adaptation for the future of the epidemic (64, 73). These
and other ﬁndings have led to recommendations that escape in-
formation be incorporated into HIV-1 vaccine strategies, for ex-
ample, via immunogens that incorporate variant sequences (13,
100) and/or that are located in mutationally constrained regions
where viral escape mutations would be anticipated to incur sub-
stantial ﬁtness costs (7, 30, 102).
Although population-level studies have signiﬁcantly advanced
our understanding of the speciﬁc mutational pathways whereby
HIV-1 escapes from HLA-restricted immune pressures, much re-
mainstobelearned.Thekeytofurtherexploringthesedataliesin
therecognitionthatHLA-associatedpolymorphismsidentiﬁedat
the population level serve as markers of viral sites under strong in
vivo immune pressure by individual HLA alleles—sufﬁciently
strong that the virus responds by escape. As such, analysis of the
distribution, frequency, location, statistical strength, and se-
quenceconservationofHLA-associatedpolymorphicsitesidenti-
ﬁedatthepopulationleveloffersauniqueperspectivefromwhich
to identify (albeit indirectly) speciﬁc features that render certain
immune responses more effective at controlling HIV progression
than others. In other words, systematic analysis of HLA-driven
evolutionary “imprints” on the HIV proteome can help identify
correlates of protective cellular immunity.
In the largest population-level, proteome-wide analysis of im-
mune escape in HIV-1 undertaken to date, we reﬁne existing im-
muneescapedatabyreportingHLA-associatedpolymorphismsat
HLA supertype-, type-, and subtype-level resolutions across the
viral proteome in an HIV-1 subtype B context. We analyze this
well-powered data set to investigate the characteristics of HLA-
driven immune selection on HIV-1 in order to draw inferences
regarding the general mechanisms HIV-1 uses in vivo to evade
such pressures. Furthermore, by treating escape mutation path-
ways as evolutionary markers of strong HLA-restricted immune
pressure by CTL, we identify speciﬁc features of these responses
that differentiate protective from nonprotective HLA class I al-
leles.
MATERIALS AND METHODS
IHAC. The International HIV Adaptation Collaborative (IHAC) is an
openmulticentercohortofchronicallyinfectedantiretroviral-naïveindi-
viduals from Canada, the United States, and Australia for whom HLA
class I and nearly full-genome HIV plasma RNA sequences have been
characterized. The present study was restricted to 1,888 HIV-1 subtype
B-infected individuals (95% of total cohort), including 1,103 individu-
als from the British Columbia HOMER cohort (British Columbia, Can-
ada) (19, 20), 247 individuals from the Western Australian HIV Cohort
Study (WAHCS; Western Australia, Australia) (13, 77, 84), and 538 U.S.
AIDS Clinical Trials Group (ACTG) protocol 5142 participants (4, 60)
who also provided human DNA under ACTG protocol 5128 (51). This
newly expanded cohort is approximately one-third larger than that stud-
ied in 2009 (20) and now features full-proteome HIV coverage. Ethical
approvalwasobtainedfromProvidenceHealthCare/UniversityofBritish
Columbia (HOMER cohort), Royal Perth Hospital Ethics Committee
(WAHCS), and the NIH’s National Institute of Allergy and Infectious
Diseases (NIAID) Clinical Science Review Committee (CSRC) (ACTG
5142/5128).
HIV-1 sequencing.Nearly full-genome plasma HIV-1 RNA sequenc-
ing (all regions except gp120) for the HOMER cohort was performed at
the BC Centre for Excellence in HIV/AIDS (BCCfE) as described in ref-
erence 20. Brieﬂy, HIV RNA was extracted from plasma using standard
methods, and regions of interest were ampliﬁed by nested reverse tran-
scription-PCR (RT-PCR) using HIV-speciﬁc primers. Amplicons were
bulk sequenced on an Applied Biosystems 3100, 3700, and/or 3730xl au-
tomated DNA sequencer. Data were analyzed using Sequencher software
(Genecodes) or the custom software RECall (120). Nucleotide mixtures
were called if the secondary peak height exceeded 25% of the dominant
peak (Sequencher) or if the secondary peak area exceeded 20% of the
dominant peak (RECall). Nearly full-genome HIV-1 sequencing for the
WAHCS and ACTG 5142/5128 cohort participants was performed at
the Centre for Clinical Immunology and Biological Statistics (CCIBS)
laboratory in Perth, Australia, as previously described (20, 60). Plasma
HIV RNA was extracted using standard methods, and nearly complete
viralgenomeswereampliﬁedusingnestedRT-PCR.Ampliconswerebulk
sequenced using an Applied Biosystems 3730xl automated sequencer.
Data were analyzed using semiautomated ASSIGN software with a nucle-
otide mixture threshold of 15% after consideration of the signal/noise
ratio, yielding nearly full-genome sequences. The BCCfE and CCIBS pre-
viously undertook blinded interlaboratory genotyping quality control
comparisons and observed excellent intersite concordance (20; also un-
published data).
Non-subtype B sequences were identiﬁed by comparison to subtype
references in the Los Alamos HIV Database using the Recombination
Identiﬁcation Program (RIP [http://www.hiv.lanl.gov/content/sequence
/RIP/RIP.html]) and removed from the analysis. HIV-1 sequences were
aligned to subtype B reference strain HXB2 (GenBank accession number
K03455). Final HLA/HIV sequence data set sizes were as follows: Gag,
1,548 sequences; Pol, 1,799 (protease/reverse transcriptase [PR/RT],
1,786; integrase [INT], 1,566); Nef, 1,685; Vif, 1,325; Vpr, 1,310; Vpu,
1,243; gp120, 655; gp41, 1,425; Tat, 1,734; and Rev, 1,731. HIV-1 se-
quences from the ACTG, Perth, and HOMER cohorts were previously
deposited in GenBank (3, 19–21, 60). Accession numbers for additional
HOMER sequences are JX147023 to JX147784 (gp41), JX147785 to
JX148365 (Tat/Rev exon 1 region), JX148366 to JX148914 (Vpu), and
JX148915 to JX149509 (Vif). Linked HLA/HIV data sets from the BC
HOMER cohort are available for sharing with interested researchers in
accordance with UBC/Providence Health Care Research Ethics Board
protocols (please contact the corresponding author for information).
HLA class I sequence-based typing and subtype imputations. HLA
class I typing for the HOMER cohort was performed at the BCCfE using
anin-housesequence-basedtypingprotocolandinterpretationalgorithm
(19,20,32),yieldingamixtureofintermediate-andhigh(subtype-level)-
resolution data. High-resolution HLA class I typing for the WAHCS and
ACTG 5142/5128 cohorts was performed at the CCIBS as previously de-
scribed (20, 60). Allele interpretation was performed using ASSIGN (60).
In previous studies we had addressed the issue of mixed-resolution
HLA data by truncating all data to the two-digit (type) level (19–21).
However,inthepresentstudywewishedtoidentifyHLA-associatedpoly-
morphisms at the supertype and subtype levels, which requires high-res-
olution data. Therefore, for all individuals with missing or low- or inter-
mediate-level resolution at one or more loci (711 of 1,888; 38%), we
employed a machine learning algorithm trained on a data set of complete
high-resolution HLA-A, -B, and -C types from 13,000 individuals with
known ethnicity (75) (available at http://research.microsoft.com/en-us
/projects/bio/mbt.aspx#HLA-Completion) to complete the data to high
resolution at all loci. The resulting output lists the inferred possible
HLA-A, -B, and -C haplotypes, along with their respective probabilities,
foreachindividual.Ratherthanassigningindividualstheirhighest-prob-
abilityHLAhaplotypes,downstreamanalysesincorporateallHLAhaplo-
types with probabilities of 1% as weighted averages for each individual.
HLA types could not be imputed when data were missing from two (or
more)loci.Insuchcases,anHLAhaplotypecontainingnullvaluesforthe
missing data and a probability of 1.0 were used.
Identiﬁcation of HLA-associated polymorphisms. HLA-associated
polymorphismswereidentiﬁedusingphylogeneticallyinformedmethods
as previously described (20, 24–26), with some modiﬁcations. Brieﬂy, a
maximum-likelihood phylogenetic tree is constructed for each gene, and
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 a model of conditional adaptation is inferred for each observed amino
acid at each codon. In this model, the amino acid is assumed to evolve
independently along the phylogeny until it reaches the observed hosts
(tree tips). In each host, the selection pressure arising from HLA-medi-
atedT-cellresponsesandaminoacidcovariationisdirectlymodeledusing
a weighted logistic regression, in which the individual’s HLA repertoire
and covarying amino acids are used as predictors, and the bias is deter-
mined by the transmitted sequence (26). Because the transmitted se-
quence is not observed, we average over the possible transmitted se-
quences, as inferred from the phylogeny.
We extended this approach to incorporate predicted high-resolution
HLA data as follows. For each subject in the cohort, a number of “frac-
tional” individuals are generated, representing each possible transmitted
polymorphism as well as each possible completed HLA repertoire, with
fractional weights representing the probability of observing the given
HLA repertoire and transmitted polymorphism, as determined by the
HLA completion (see above) and phylogeny, respectively. When the ob-
served polymorphism represents a mixture, we extend the weighting
scheme to represent all possible mixture outcomes, with relative weights
inverselyproportionaltothenumberofaminoacidsinthemixture.Max-
imum-likelihood estimation for logistic regression and phylogenetic pa-
rameters is jointly estimated using expectation maximization (34).
To identify which factors contribute to the selection pressure, a for-
ward selection procedure is employed, in which the most signiﬁcant as-
sociation is iteratively added to the model, with P values computed using
the likelihood ratio test. To increase our statistical power, each codon is
dividedintoasetofbinaryvariables,oneforeachobservedaminoacid.In
addition, we consider only HLA alleles and amino acids that are observed
in at least 10 individuals in the population or for which at least 10 indi-
viduals do not express the HLA or polymorphism. In the case of imputed
HLA alleles, we use the expected number of individuals expressing that
allele, where expectation is taken with respect to the HLA completion
probability. Statistical signiﬁcance is reported using q values, the P-value
analogue of the false-discovery rate (FDR), for each P-value threshold
(114).TheFDRistheexpectedproportionoffalsepositivesamongresults
deemed signiﬁcant at a given threshold; for example, at a q of 0.2, we
expect 20% of identiﬁed associations to be false positives. We compute q
values separately for each protein.
HLA-associated polymorphisms are grouped into two categories: (i)
amino acids signiﬁcantly enriched in the presence of the HLA allele in
question (“adapted” forms) and (ii) amino acids signiﬁcantly enriched in
the absence of the HLA allele in question (“nonadapted” forms). To pro-
vide an example, the B*27-associated R264K is a well-known escape mu-
tation that commonly occurs at position 2 of the KK10 epitope in p24
Gag
(65). At this codon, “R” represents the B*27-associated nonadapted form
while K represents the B*27-associated adapted form. In general, non-
adapted forms correspond to the subtype B consensus sequence while
adaptedformscorrespondtopolymorphicvariants,butexceptionsoccur.
In addition, we will sometimes differentiate between “direct” and “indi-
rect” HLA-associated polymorphisms: the former represent associations
that are detected when HIV sequence covariation is considered, and the
latterariseonlywhencovaryingaminoacidsarenotconsidered(andthus
may include compensatory mutations). Analyses in this paper employ all
observed direct and indirect associations.
Verifying the impact of HLA imputation on the ability to identify
HLA-associatedpolymorphisms.Asdescribedabove,somelevelofHLA
imputationwasrequiredfor711of1,888(38%)individualsinthepresent
study. To investigate the impact of HLA imputation on identiﬁcation of
HLA-associated polymorphisms in a “worst-case” scenario, we took the
subsetofpatientsforwhomfullhigh-resolutiondatawereavailable(1,177
patients),truncatedallHLAtypestotwo-digitresolution,andreimputed
them to high resolution. The highest-probability imputed allele matched
theoriginalcallin93%ofcases.WethenidentiﬁedHLA-associatedpoly-
morphisms from the imputed data set and compared to those obtained
from analysis of the same data set at high resolution (data not shown).
When comparing unique HLA (type)-HIV codon pairs, 82% of associa-
tions derived from the imputed data set matched those derived from the
high-resolutiondataset,aresultthatisexpectedgiventhefalse-discovery
rateof0.2andtheexpectedlossofstatisticalpowerwhenimputeddataare
analyzed.
Testing for differential escape. The statistical model for differential
escape among HLA subtypes belonging to a given allele group (type) was
deﬁned as previously described (26). However, whereas the previous
study (26) explicitly investigated differential escape within published
epitopes, here we tested for differential escape in general across the entire
proteome, that is, cases where one subtype selects a given polymorphism
and another does not select for that polymorphism or selects for that
polymorphism at a lower frequency. As such, differential escape in the
present context could be due to less effective (or lack of) responses to
speciﬁcepitopes.Brieﬂy,thephylogeneticallycorrectedlogisticregression
model was used to test for evidence that the odds of selection differed
between an HLA type and a particular subtype. For example, to test if the
probability P of escape to 242N (in p24
Gag) differed between B*58:01 and
the rest of the B*58 subtypes, we used the phylogenetically corrected lo-
gistic regression model deﬁned by the following: ln[P/(1  P)] 
a(B58)  b(B5801)  cT, where T is a 1/1 binary variable representing
the transmitted polymorphism, B58 and B5801 are 0/1 binary variables
indicating whether the individual has the HLA allele in question, and the
parameters(a,b,andc)arechosentomaximizethelikelihoodofthedata.
The likelihood ratio was then used to test the null hypothesis that b  0
(i.e., that knowing that an individual expresses B*58:01 confers no addi-
tional information beyond knowing that the individual expresses B*58).
To validate the distinction between associations identiﬁed at type-
versus subtype-level resolution, we applied the above model as follows.
Foreachassociationoriginallyidentiﬁedatthesubtypelevel,wetestedfor
differential escape between the identiﬁed subtype and the corresponding
HLA type. If the resulting q value was less than 0.2, we considered the test
an instance of true differential escape (differential escape was conﬁrmed
in80%ofcaseswhereescapewasoriginallydeﬁnedatthesubtypelevel).
For each association originally deﬁned at the type level, we tested for
differential escape against all subtypes observed in at least 10 individuals
inthesubsetforwhomhigh-resolutionHLAdatawereavailableacrossall
loci (1,177 of 1,888 subjects, or 62%). Together, a total of 29 HLA types
with at least two subtype members were available for analysis. If the q
valueofthemostsigniﬁcantsuchtestwaslessthan0.2,weconsideredthe
HLA-polymorphismpairtorepresentatrueinstanceofdifferentialescape
(a reclassiﬁcation that occurred in 20% of cases where escape was orig-
inally deﬁned at the type level). For both positional analyses and analyses
involvingthestratiﬁcationoftestsbyHLAtype,welimitedtheanalysisto
the most signiﬁcant HLA-type/HIV-position pair to avoid double count-
ing nonadapted/adapted pairs.
Calculation of median genetic distances among HLA alleles of a
given type. To estimate relative protein distances among HLA subtypes
included in our differential escape analysis (see above), we retrieved their
exon 2 and 3 amino acid sequences from http://hla.alleles.org/data/txt
/classi_prot.txt (98) and used the protdist program from the PHYLIP
software package (41) to calculate pairwise distances using the Henikoff
Tillier probability matrix from blocks (PBM) model of amino acid re-
placement (119). For each HLA allele group (type), the median pairwise
genetic distance between subtype members (intratype distance) was cal-
culated.
Deﬁnition of optimally deﬁned CD8
 epitopes. The Los Alamos op-
timalCD8
epitopelistcomprisesallpublishedepitopesdeﬁnedaccordingto
rigorous in vitro epitope ﬁne-mapping and HLA restriction experiments
(http://www.hiv.lanl.gov/content/immunology/tables/optimal_ctl
_summary.html; 31 August 2009 update) (76). However, optimal epitopes
have not necessarily been tested in context of all possible restricting HLA
alleles, nor are the alleles deﬁned at the same resolution (i.e., HLA type, sub-
type, or serotype) throughout. To address these biases (and in recognition
thatalleleswithsharedpropertiesarelikelytopresentsimilarpeptides(111),
Carlson et al.
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 we expanded each optimal epitope to include all members of the HLA type,
supertype, or serotype to which the published restricting allele belonged, as
described in reference 26. Brieﬂy, optimally deﬁned epitopes were retrieved
fromtheLosAlamosDatabaseandhandeditedtoincluderecentlypublished
epitopes (22, 48, 55, 66, 69, 74, 79, 105; also A. Bansal and P. Goepfert, per-
sonal communication). For optimal epitopes restricted by HLA alleles de-
ﬁnedattype-orsubtype-levelresolution,weexpandedtoincludeallsubtypes
belongingtothesupertypetowhichtherestrictingallelebelonged(111).For
example,anepitopeoriginallydeﬁnedasB*57:01restrictedwasassignedtoall
membersoftheB58supertype.Forepitopesrestrictedbyallelesdeﬁnedatthe
serotypelevel(n38),weexpandedthelisttoincludeallHLAallelesbelong-
ing to that serotype (54), identiﬁed supertypes common to a majority of the
resulting expansion, and expanded the list to include all subtypes matching
those supertypes. If no supertype was deﬁned (as is the case for HLA-C al-
leles),weexpandedthelisttoincludeallHLAsubtypesbelongingtotheHLA
typeoftheoriginalrestrictingallele.Thefulllistofexpandedepitopes(along
with their original restrictions) is provided in Table S1 in the supplemental
material.
Analysis of population-level immune escape pathways to identify
correlatesofprotectiveimmunity:datadeﬁnitions.Protectiveeffectsof
speciﬁc HLA class I alleles on HIV progression were deﬁned according to
published hazard ratios for progression to AIDS (HR-AIDS), determined
for54individualclassIallelesattype-level(2-digit)resolutioninanatural
history cohort of 600 Caucasian seroconverters (89). To allow analysis at
subtype-levelresolutionusingHLA-associatedpolymorphismsspeciﬁcto
the population in which HR-AIDS were originally derived, we assigned
eachHRtothemostfrequentlyobservedHLAsubtypeinCaucasians(e.g.,
A*02 was assigned to A*02:01) and analyzed only HLA-associated poly-
morphismsrestrictedbythesesubtypes.Inbothunivariateandmultivar-
iate analyses, HR-AIDS values were log transformed to render their dis-
tribution more normal.
HLA-associated polymorphism-related variables that we investigated
could be classiﬁed into two broad categories: features related to the fre-
quency and/or distribution of sites under selection by a given HLA allele
(deﬁned as unique HIV codons harboring a polymorphism associated
with that HLA allele) and features related to the signal strength of sites
underHLAselectionand/ortoevolutionaryconstraintsonthesitesthem-
selves. The ﬁrst category contained the following variables: (i) number of
sites under HLA selection (computed as the total number of HLA-associ-
ated polymorphic sites in HIV-1, both overall and within/near published
epitopes only); (ii) proportion (percent) of sites under HLA selection, by
protein (computed as the proportion of the total HLA-associated sites
occurring within the HIV-1 protein of interest); (iii) number of sites un-
der HLA selection occurring at anchor residues (computed as the total
number of HLA-associated sites occurring at anchor positions within
known epitopes); (iv) proportion (percent) of sites under HLA selection
occurring at anchor residues (proportion of total HLA-associated sites
inside or within  3 amino acids [aa] of an epitope that occurred at an
anchorposition);(v)numberofactiveepitopes(deﬁnedasthenumberof
published epitopes harboring HLA-associated polymorphisms); and (vi)
median number of sites under HLA selection per active epitope. The sec-
ond category contained the following variables: (vii) median odds ratio
(OR) of selection (computed by taking the maximum absolute log odds
ratio of all nonadapted and adapted associations per HLA at each unique
site, followed by computing the median of all sites per HLA, where the
oddsratioforagivenHLA-polymorphismpairwascomputedastheratio
oftheoddsofobservingthepolymorphismamongindividualsexpressing
the allele to the odds of observing the polymorphism among individuals
not expressing the allele); (viii) median conservation of sites under HLA
selection (deﬁned as the median sequence conservation of all sites associ-
ated with a particular HLA, where conservation was deﬁned to be the
proportionofindividualswiththeconsensussequenceamongindividuals
who did not express any HLA alleles associated with that site) (102); and
(ix)mediannumberofcovaryingcodonspersite(computedbysumming
thenumberofuniqueHIV-1codonsidentiﬁedascovaryingwitheachsite
and computing the median for all sites per HLA). Where appropriate,
analyseswereundertakenatboththeproteome-wideandindividual-pro-
tein levels (deﬁned as Gag, Pol, Env, Nef, and accessory) to identify loca-
tion-speciﬁc correlates of protection.
Multivariateanalyseswereattemptedusingasmallnumberofdistinct
variables signiﬁcant at the univariate level. To maximize the number of
HLA alleles included in the multivariate analysis, alleles with “missing”
variables (e.g., those excluded from the original univariate analysis of OR
of escape in Gag because they possessed no escape sites in that protein)
were assigned the mean observed value in the data set. Selected variables
were regressed against log-transformed HR-AIDS values by automated
forward selection using a stepwise Akaike information criterion (AIC)
procedure (2).
RESULTS
IdentiﬁcationofHLA-associatedpolymorphismsatthreelevels
of HLA resolution. HLA-associated polymorphisms were identi-
ﬁed across the entire HIV-1 proteome in an international cohort
of 1,888 treatment-naïve, chronically subtype B-infected individ-
uals using phylogenetically informed methods that incorporated
corrections for HIV codon covariation and HLA linkage disequi-
librium (20, 25, 26) and used a q-value correction for multiple
tests (114). Missing or low- or incomplete-resolution HLA data
were imputed to subtype-level resolution using a published ma-
chinelearningalgorithm(75),andassociationswerecomputedby
averaging over all possible HLA resolutions (see Materials and
Methods); this represents the ﬁrst use of HLA completion algo-
rithms in population-level immune escape analyses.
Studies of HLA-associated polymorphisms have generally fea-
tured individual pairwise analyses at the HLA type (i.e., 2-digit)
and/or subtype (i.e., 4-digit) levels (19, 20, 25, 104). Supertype-
levelanalyseshavebeenuncommoneventhoughstatisticalpower
could be enhanced to identify universal escape pathways within
epitopes capable of binding related alleles. We therefore report
HLA-associated polymorphisms at three different levels of reso-
lution: ﬁrst, at the combined supertype/type/subtype levels; sec-
ond;atthecombinedtype/subtypelevels;andthird;atthesubtype
level only. In the ﬁrst two analyses, the level of resolution yielding
the lowest P value for each HLA-associated polymorphism is re-
ported(thatis,ifthestatisticalsignalfortheassociationisstronger
at the supertype than at the type or subtype level, then it is re-
ported at the supertype level). A full list of HLA-associated poly-
morphismsidentiﬁedatallthreelevelsofresolutionisprovidedin
TableS2inthesupplementalmaterial,whileafulllistofintrapro-
tein codon covariation pathways is provided in Table S3. In addi-
tion, protein-speciﬁc immune escape maps for all associations
with a q of 0.05 identiﬁed at the broadest (supertype/type/sub-
type) resolution level analysis are provided in Fig. S1 in the sup-
plemental material.
Ataqof0.2,over2,100uniqueHLA-associatedescapepath-
ways (deﬁned as those unique over HLA restriction, HIV codon
coordinate,aminoacid,anddirectionofescape)occurringatover
750HIV-1codonswereidentiﬁed(seeTableS2).Whentheinher-
ent sequence conservation of each HIV protein was taken into
consideration, the proportion of sequence variation attributable,
atleastinpart,toHLAselectionpressures(deﬁnedasthepropor-
tion of sites harboring at least one HLA-associated polymor-
phism) differed markedly by viral protein (Fig. 1). For example,
with59%ofitsresiduesexhibiting 99.5%aminoacidconserva-
tion, p24
Gag is the most highly conserved HIV-1 protein, yet HLA
pressures inﬂuence sequence variation at 40% of its variable
Lessons from Immune Escape in HIV-1
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 codons. HLA-mediated polymorphisms were observed most fre-
quently in the highly immunogenic Nef protein, where 67.4% of
variable codons harbor HLA associations (P  1.9  10
18; Fish-
er’sexacttestcomparedtootherproteins).Conversely,thehighly
variable Vpu protein exhibited the least evidence of HLA-driven
evolution (26.3% [P  0.009]) (Fig. 1)( 19, 52, 60). Across the
entire HIV-1 proteome, polymorphisms at 804 of 1,481 (35.2%)
variable sites were associated with at least one HLA allele.
TheextentofdifferentialCTLescapebetweensubtypemem-
bers varies markedly by HLA. Although the HLA-associated
polymorphisms identiﬁed at the three different levels of HLA res-
olution are highly concordant (see Table S2 in the supplemental
material), each analysis features relative merits and limitations.
Analysis at broader resolution can enhance statistical signal when
related alleles bind the same epitope and escape along the same
pathway. For example, the Gag-TW10 epitope binds many mem-
bers of the B58 supertype. At Gag codon 242 (position 3 of this
epitope),relativeoddsofescapeare193:1forB58supertypemem-
bers compared to non-B58 supertype members (P  1.6 
10
117). However, when relative odds are calculated at the type
(e.g., B*57) or subtype (e.g., B*57:01) level, lower odds are ob-
served (128:1, P  1.2  10
87, and 114:1, P  5.4  10
72,
respectively) because persons harboring closely related alleles
(e.g., B*58 and/or B*58:01) are classiﬁed as lacking the speciﬁc
allele under investigation even though they also select the same
escape mutation. Conversely, when alleles belonging to the
same type or supertype bind different peptides or select differ-
ent escape pathways, analyzing at broader resolution may yield
inappropriate results while still achieving high levels of statis-
ticalsigniﬁcanceandmaymaskdifferentialescape(wheresim-
ilarHLAallelesbindthesameepitopebutescapealongdistinct
pathways) (26). For example, despite belonging to the B58 su-
pertype,B*58:02doesnotselectfortheT242Nescapemutation
(see Table S2).
Notably, even when analyzed at the broadest resolution level,
the majority of HLA-associated polymorphisms (62%) are still
subtyperestricted,whileonly31%and7%aretypeandsupertype
restricted, respectively. These distributions were robust to HLA
imputation(seeMaterialsandMethodsandFig.S2inthesupple-
mental material). To characterize the extent of differential escape
between and within HLA types/subtypes across the HIV-1 pro-
teome,weappliedrecentlydevelopedtechniques(26;seealsoMa-
terials and Methods) to explicitly test for differential escape (de-
ﬁnedhereascaseswhereonesubtypeselectsapolymorphismand
another selects a different—or no—polymorphism at any given
codon). Overall, we estimate that when polymorphisms are iden-
tiﬁedatthetypelevel,thereisan81.5%chancethatnodifferential
escape occurs at the subtype level. Conversely, when polymor-
phismsareidentiﬁedatthesubtypelevel,thereisan81.2%chance
that the subtype of interest indeed displays a signiﬁcant differen-
tial escape pattern compared to the type as a whole (data not
shown). Given our 20% false-discovery rate signiﬁcance thresh-
old, results indicate that our method of reporting associations at
thelevelofresolutionyieldingthelowestPvalueisbroadlyappro-
priate. Stratifying analyses by individual HLA alleles revealed that
the heterogeneous B*15 type exhibited the most evidence for dif-
ferential escape (with over 85% of pathways being unique at the
subtype level) while B*07 exhibited the least (with only 20% of
pathways being unique at the subtype level) (Fig. 2A). Overall,
differential CTL escape was widespread at the subtype level, with
allelegroupmembersexhibitingdistinctescapemutationsin58%
of the cases on average (HLA-A, 63%; HLA-B, 55%; HLA-C,
60%).
TheunderlyingmechanismsthatdrivedifferentialCTLescape
areunclearandmayincludedifferencesinepitopebinding,T-cell
receptor (TCR)-HLA-epitope interactions, TCR repertoire, or
may reﬂect differences that result from linkage of certain HLA
subtypes to other factors, such as antigenic exposure, antigenic
processing,orlinkagewithotherHLAclassIorclassIIalleles(26).
In support of a mechanism that involves properties of the HLA
alleles themselves, we observed a striking positive correlation be-
tween the overall genetic divergence of HLA exons 2 and 3 (the
major genetic determinants of the peptide-HLA binding groove)
between allele group members (see Fig. S3 in the supplemental
material) and the frequency of differential escape between them
(Spearman R  0.60; P  0.0043) (Fig. 2B).
FIG 1 The proportion of sequence variation attributable to HLA-associated selection pressures differs markedly by HIV-1 protein. The proportion of codons
exhibiting 99.5% amino acid conservation at the population level in our cohort and the proportion of variable codons (those exhibiting 99.5% amino acid
conservation) harboring no known HLA-associated polymorphisms are indicated, along with the proportion of codons harboring at least one HLA-associated
polymorphism. Numbers in parentheses in the x-axis labels indicate the total length in amino acids of each protein (including the stop codon, if present). **, P
 0.001; ***, P  0.0001 (Fisher’s exact test compared to all other proteins combined).
Carlson et al.
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 Enrichment of escape at epitope-HLA anchor residues. We
next examined the distribution and positioning of HLA-associ-
atedpolymorphismswithrespecttoCTLepitopes(76).Ourinitial
epitope reference list consisted of all optimally described CTL
epitopes restricted by one or more HLA class I alleles. We then
expanded this list by assigning the published epitope to all allele
groupmembers(i.e.,subtypes)belongingtotheHLAallelegroup
(i.e., supertype, type, or serotype, depending on the published
restriction) to which the original published epitope belonged (see
Materials and Methods and Table S1 in the supplemental mate-
rial). For example, an epitope originally deﬁned as B*57:01 re-
strictedwasassignedtoallmembersoftheB58supertype.Sinceall
epitopes on our expanded list were deﬁned at subtype-level reso-
lution, we utilized the subtype-level HLA-associated polymor-
phism list in the following analysis although sensitivity analyses
conﬁrmed that results were consistent regardless of the associa-
tion list used (data not shown).
Ofthe2,161HLA-restrictedviralescapepathwaysidentiﬁedat
subtype-level resolution, 29% occurred inside or within 3 resi-
duesofanoptimallydescribedCTLepitope.Thisvaluewas21.5%
when epitope expansion was not undertaken. In support of in-
cluding ﬂanking regions in the epitope deﬁnition, a bootstrap
analysis (100,000 replicates) indicated that escape frequency at
epitopeﬂankingresidueswassigniﬁcantlyhigherthanescapeout-
side epitopes and their immediate ﬂanking regions for HLA-B
alleles(P0.00012)thoughthiswasnotsigniﬁcantforHLA-Aor
-Calleles.Becausethemajorityofdeﬁnedepitopesare9-mers,we
ﬁrst examined these. Of the 262 unique 9-mer HLA-epitope pairs
(deﬁned as epitopes restricted by the same HLA supertype and
mappingtothesameHIVcoordinates)forwhichanHLA-associ-
ated polymorphism was identiﬁed, positions 2 and 3 and the C
terminus represented the most frequently escaping sites, while
escapeatN-terminalﬂankingresidue3andC-terminalﬂanking
residue2waslessfrequentthanexpectedunderthenullhypoth-
esis of equal escape frequency across all sites within/ﬂanking
epitopes (binomial test for departure from expected 1/15 fre-
quency,allP0.01)(Fig.3A).Stratiﬁcationbylocusrevealedthat
HLA-A-restricted epitopes tended to select for escape mutations
at position 3 and the C terminus, HLA-B-restricted epitopes typ-
ically developed escape mutations at position 2, and the limited
number of HLA-C epitopes most often encoded C-terminal es-
cape mutations (see Fig. S4 in the supplemental material).
Classiﬁcation of escape mutations with respect to their posi-
tion at an anchor residue (deﬁned according to HLA subtype-
speciﬁc anchor motifs available at http://www.hiv.lanl.gov
/content/immunology/motif_scan/motif.html)( 37, 78, 91, 110)
revealed that escape occurred at anchor residues 1.8-fold more
frequentlythanexpectedunderthenullhypothesisofequalescape
frequency across all sites within/ﬂanking epitopes (binomial test
fordeparturefromexpected2/15frequency,P1.010
5)(Fig.
3B) and 1.4-fold more frequently than expected across all sites
within the epitope only (binomial test for departure from ex-
pected2/9frequency,P0.003)(datanotshown).Thefrequency
of escape at N- and C-terminal epitope ﬂanking residues was
nearly 2-fold lower than that expected under the null hypothesis
of equal escape frequency across all sites within/ﬂanking epitopes
(binomial test for departure from expected 6/15 frequency, P 
1.010
5)(Fig.3B).Moreover,theaveragestatisticalstrengthof
escape at anchor sites (measured as the maximum absolute natu-
ral-log-transformedoddsratio[lnOR]foreachuniqueHLA-HIV
codon pair) was modestly yet signiﬁcantly increased compared to
that of nonanchor or ﬂanking sites (median lnOR of 2.15 [inter-
quartile range (IQR), 1.15 to 2.58] for anchor sites versus 1.62
[IQR, 0.93 to 2.35] for nonanchor sites versus 1.30 [IQR, 0.81 to
1.98] for ﬂanking regions; Kruskal-Wallis, P  0.035) (Fig. 3C).
Epitopes of other lengths (8-, 10-, and 11-mer [8/10/11-mer];
n  201) were also examined. To ensure alignment of anchor
residues, positions were analyzed with respect to their distance
fromtheNandCtermini.Relativelyuniformfrequencyofescape
was observed at epitope positions 1 to 4 and at the penultimate
and C-terminal positions, while escape at position C3 (three
positions upstream of the C terminus) was relatively rare (Fig.
FIG2 WidespreaddifferentialescapebetweenHLAallelegroupmemberscorrelateswithevolutionarydistancebetweenHLAgenes.IndividualHLA-A,-B,and
-Ctypesareindicated.Theproportionofdifferentialescape(deﬁnedastheproportionofHLA-associatedpolymorphismsforwhichtheoddsofescapediffered
signiﬁcantlybetweenatleastoneHLAsubtypeandtherestofthegroup)differsmarkedlyforvariouscommontypesoftheHLA-A,-B,and-Cloci(A).HLAtypes
exhibitingthehighestlevelofdifferentialescapewerethoseexhibitingthegreatestintratypegeneticdiversity(B).HLA-B*07andB*15(exhibitingthehighestand
lowest proportion of differential escape, respectively) and B*40 are labeled for special interest.
Lessons from Immune Escape in HIV-1
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 3D). When analyzed separately, 10-mers tended to escape more
frequently at position 3 but not the C terminus, while 11-mers
tended to escape more frequently at position 4 (see Fig. S4 in the
supplemental material), an observation that may be due to the
bulging of oversized epitopes and its effect on TCR contacts (83).
Overall, a 1.45-fold enrichment of escape mutations at anchor
residueswasobservedcomparedtoothersiteswithinandﬂanking
the epitopes (P  0.014) (Fig. 3E); however, this did not remain
signiﬁcant when analysis was restricted to within-epitope sites
only(P0.3)(datanotshown).Theaveragestatisticalstrengthof
escape (lnOR) did not differ signiﬁcantly between anchor and
nonanchor sites for 8-, 10-, and 11-mer epitopes (median lnOR
was between 1.4 and 1.5 for all positions; P  0.89) (Fig. 3F).
EstimatingtheeffectofanchorresidueescapeonHLAbind-
ing. Given the enrichment of CTL escape mutations at HLA an-
chor residues, we next estimated the extent to which these muta-
tions were predicted to affect peptide-HLA binding using
NetMHCpan2.4, an artiﬁcial neural network-based peptide-HLA
binding prediction tool trained on 37,000 quantitative binding
data for more than 42 different HLA molecules (88). For each
HLA-associated adapted polymorphism that occurred inside an
epitope (147 9-mers and 133 8/10/11-mers), we compared the
predicted HLA binding afﬁnity for the published epitope in its
HLA-restricted nonadapted (i.e., susceptible) versus its HLA-as-
sociatedadapted(i.e.,escaped)form,usingthesubtypeBconsen-
sus for the epitope backbone (in cases where no HLA-restricted
nonadapted residue was identiﬁed, the subtype B consensus resi-
due was used). After removing epitopes predicted to bind the re-
stricting HLA with a 50% inhibitory concentration (IC50)o f
1,000nMintheirnonadaptedform(representinga2-foldlower
afﬁnity than NetMHCpan2.4-deﬁned weak binding threshold,
which included 30 9-mers and 38 8/10/11-mers), we calculated
that anchor residue escape in 9-mer epitopes was predicted to
reducepeptide-HLAbindingbyamedianof8.9-fold(IQR,3.7-to
52.1-fold)comparedto1.25-fold(IQR,0.80-to1.99-fold)atnon-
anchor sites (Fig. 4A). Among 8/10/11-mer epitopes, anchor res-
idue escape was predicted to reduce peptide binding a median of
8.9-fold (IQR, 1.9- to 114.3-fold) compared to 1.0-fold (IQR,
0.87- to 1.56-fold) at nonanchor sites (Fig. 4B). Overall, 36 out of
212 (17%) within-epitope escape mutations were predicted to
“completely” abrogate peptide-HLA binding, deﬁned as epitopes
which bound with an IC50 of 1,000 nM afﬁnity in their non-
adapted form but an IC50 of 1,000 nM afﬁnity in their escaped
form (data not shown).
FIG 3 The distribution and natural log odds ratio of escape within known epitopes is nonuniform and biased toward anchor residues. The distribution and
natural log odds ratio of escape mutations within known CD8
 9-mer epitopes (A, B, and C) and 8-/10-/11-mer epitopes (D, E, and F) are shown. Frequencies
of escape by relative position within or occurring at the 3 amino acids ﬂanking the epitope N and C termini are depicted as histograms in panels A and D. In
panel D, notation of the type C3o nt h ex axis indicates the number of positions upstream of the C terminus (in this case, 3). These same data are depicted as
fold differences from expected frequency of escape occurring at HLA-speciﬁc anchor, nonanchor, and epitope ﬂanking positions (based on the null hypothesis
ofequalescapeprobabilityacrossallpositions)andareshowninpanelsBandE.*,P0.05;**,P0.001;***,P0.0001(binomialtest).Thenaturallogofthe
odds ratio of escape at HLA-speciﬁc anchor, nonanchor, and epitope ﬂanking positions are shown as scatter plots (C and F).
Carlson et al.
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 Correlates of protective immunity revealed by analysis of
population-level immune escape pathways. Expression of spe-
ciﬁc HLA class I alleles is associated with differential rates of
HIV-1 disease progression (27, 62, 89), but the precise mecha-
nismsunderlyingtheseeffectsremainincompletelyknown(6,56,
70, 93). Given that HLA-associated polymorphisms identify viral
sites under strong in vivo selection by an HLA allele at the popu-
lation level, analysis of their frequency, distribution, statistical
strength, sequence conservation, and other characteristics allows
us to identify characteristics that discriminate protective HLA al-
lele-associated immune pressures from nonprotective ones. It is
important to emphasize that, although population-level HLA-as-
sociated polymorphisms may allow us to infer speciﬁc properties,
tendencies, or attributes that render certain HLA alleles particu-
larly effective at controlling HIV, by no means are we proposing
that selection of escape mutations is beneﬁcial at the individual
patient level.
HLA-associated protective effects were deﬁned according to
published hazard ratios for progression to AIDS (HR-AIDS) de-
rivedfromalargelongitudinalnaturalhistorycohort(89;seealso
Materials and Methods). We investigated 33 interrelated features
ofviralsitesunderHLA-mediatedselectionaspotentialcorrelates
of protective immunity. These 33 features were divided into two
broad categories: those related to their frequency/distribution
(overall, and within known epitopes) and those related to the sta-
tistical strength of selection and/or mutational constraints on the
sites themselves (Table 1). Where appropriate, analyses were un-
dertaken at proteome-wide and individual-protein levels. HLA-
associated polymorphisms from the subtype-level analysis were
used.
Ofthe33variablesinvestigated,weidentiﬁed12potentialcor-
relatesofHLA-mediatedprotectiveimmunityagainstdiseasepro-
gression (P  0.05, q  0.2) (Table 1). Among the strongest cor-
relates of protection was the signiﬁcant inverse relationship
betweentotalnumberofsitesunderselectionbyagivenHLAand
its HR-AIDS (Spearman’s R  0.41; P  0.0024) (Fig. 5A),
indicating that protective HLA alleles exert substantial in vivo
pressure on a greater number of sites across the HIV proteome.
This observation was almost exclusively driven by HLA-A and -B
alleles (Spearman’s R  0.48; P  0.0016) (data not shown).
When analyzed at the individual protein level, this inverse rela-
tionship was strongest for Gag and remained signiﬁcant for all
proteins except Nef, where the trend persisted but was not signif-
icant (Table 1).
Notably, no signiﬁcant correlations were observed between
HR-AIDSandmediansequenceconservationofsitesunderselec-
tion (where the sequence conservation of a given site was deﬁned
as the proportion of the total cohort harboring the consensus
residue at this position [102]). This remained true when the bias
induced by HLA-mediated selection on these sites was addressed
by excluding persons expressing these alleles from the calculation
of conservation (Table 1). Similarly, no signiﬁcant correlations
were observed between HR-AIDS and the median number of co-
varying codons per site under selection. However, signiﬁcant in-
verse relationships were observed between an HLA allele’s HR-
AIDSandthemedianoddsratioofselectionformutationsinGag
(R  0.6, P  0.0012) (Fig. 5B) and, to a lesser extent, in Pol
(R0.34,P0.039)butnotoverallorinotherHIV-1proteins.
Another highly signiﬁcant proteome-wide correlate of protec-
tion was the tendency of protective alleles to select escape muta-
tionsatHLAanchorsiteswithinknownepitopes(Spearman’sR
0.47; P  0.0052) (Fig. 5C). This effect appeared to be largely
constrained to Pol and Gag (P  0.0015 and P  0.065, respec-
tively).Themediannumberofsitesunderselectionperepitopein
Gag, but not elsewhere in the viral genome, was also modestly
inversely correlated with HR-AIDS (Table 1).
To attempt to identify which of these features represented the
strongest independent correlates of protection, we investigated a
varietyofmultivariatemodelsincorporatingfourofourtop“hits”
(median OR of selection in Gag, median OR of selection in Pol,
number sites under selection proteome-wide, and percentage of
selected sites occurring at anchor residues). Unfortunately due to
FIG 4 Fold changes in predicted peptide-HLA binding afﬁnities following escape at anchor residues. Fold changes in predicted peptide-HLA binding afﬁnities
as a consequence of escape at HLA-speciﬁc anchor (versus nonanchor) residues within 9-mer (A) and 8-, 10-, and 11-mer (B) epitopes are shown as Tukey box
plots.
Lessons from Immune Escape in HIV-1
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 thestronginterdependencyofthesevariablesandthefactthatnot
all variables were available for all HLA alleles, multivariate analy-
seswerenotrobusttochangesinmodelselectionprocedures.The
only variable that consistently emerged as a signiﬁcant indepen-
dent predictor of protection was the number of sites under selec-
tionbyagivenHLAacrosstheHIV-1proteome(datanotshown).
DISCUSSION
HLA-associated polymorphisms identify HIV-1 sites that are un-
der consistently strong immune pressure in vivo and whose se-
quence diversity is largely driven by HLA. As such, the well-pow-
ered nature of this analysis combined with its proteome-wide
focus allowed us to study the frequency, distribution, and charac-
teristics of viral sites under HLA-mediated selection. The propor-
tionofpopulation-levelsequencevariationattributable,atleastin
part, to HLA (deﬁned as the proportion of sites in a given protein
harboring at least one HLA-associated polymorphism) differs
markedly by protein and is independent of the protein’s overall
conservation. For example, whereas the majority of variable Nef
codons are attributable, at least in part, to HLA class I-mediated
pressures, this explains only a quarter of Vpu sequence variation,
implyingtheexistenceofotherhostfactorsindrivingevolutionof
this viral gene (40, 52, 112) (to provide context, nearly 40% of
variablesitesinthehighlyconservedp24
Gagproteinareassociated
with HLA).
Building on recent advances (26, 69), we demonstrated signif-
icant variation in the proportion of differential escape among
closelyrelatedHLAsubtypes,implicatingdifferencesinTCRrep-
ertoireand/ortheinteractionbetweenTCRandtheepitope-HLA
complex as the underlying mechanisms in at least some cases
(123). Widespread differential escape is consistent with reported
differencesinHIV-1diseaseprogressionbetweenHLAallelesdif-
feringbyaslittleas1aminoacid(43,68,86)andalsosupportsthe
notionthatanalysisofHLA-associatedpolymorphismsprovidesa
novel perspective from which to discriminate both quantitative
and qualitative differences in HLA-restricted immune responses.
Of interest, HLA allele subtype pairs that exhibit the highest level
of differential escape were those with the greatest intratype se-
quencedivergence,raisingtheintriguinghypothesisthatdifferen-
tial escape may be a consequence of active positive selection at
these loci.
Analysis of the distribution of HIV-1 escape mutations within
known CTL epitopes revealed that abrogation of peptide-HLA
TABLE 1 Identifying correlates of HLA allele-associated protective immunity
Feature Category
No. of HLA
alleles analyzed Spearman RP value q value
a
Median OR of selection in Gag Strength/constraint 26 0.60 0.0012 0.04
No. of sites under selection (proteome-wide) Frequency/distribution 53 0.41 0.0024 0.04
Proportion of selected sites occurring at HLA anchor residues
(proteome-wide [%])
Frequency/distribution 34 0.47 0.0052 0.04
No. of sites under selection in Gag Frequency/distribution 53 0.38 0.0054 0.04
No. of sites under selection in accessory proteins Frequency/distribution 53 0.37 0.0058 0.04
No. of selected sites occurring at HLA anchor residues
(proteome-wide)
Frequency/distribution 44 0.35 0.018 0.10
No. of sites under selection within/near epitopes (proteome-wide) Frequency/distribution 53 0.31 0.025 0.11
No. of active epitopes in Gag Frequency/distribution 53 0.30 0.027 0.11
Median no. of sites under selection per epitope in Gag Frequency/distribution 22 0.46 0.032 0.12
Median OR of selection in Pol Strength/constraint 38 0.34 0.039 0.13
No. of sites under selection in Env Frequency/distribution 53 0.28 0.045 0.13
No. of sites under selection in Pol Frequency/distribution 53 0.28 0.046 0.13
Median conservation of selected sites in Nef Strength/constraint 38 0.29 0.079 0.20
Median conservation of selected sites in accessory proteins Strength/constraint 45 0.24 0.11 0.25
Median conservation of selected sites in Env Strength/constraint 32 0.28 0.13 0.28
No. of ites under selection within/near epitopes in Gag Frequency/distribution 28 0.27 0.16 0.33
No. of active epitopes (proteome-wide) Frequency/distribution 53 0.17 0.23 0.41
Median no. of covarying codons per selected site (proteome-wide) Strength/constraint 51 0.17 0.23 0.41
Median no. of sites under selection per epitope (proteome-wide) Frequency/distribution 44 0.18 0.24 0.41
Median conservation of selected sites in Nef Strength/constraint 51 0.16 0.25 0.42
Proportion of sites under selection in Gag (%) Frequency/distribution 51 0.14 0.33 0.50
Proportion of sites under selection in Env (%) Frequency/distribution 51 0.13 0.35 0.50
Proportion of sites under selection in Nef (%) Frequency/distribution 51 0.13 0.36 0.50
Proportion of sites under selection in accessory proteins (%) Frequency/distribution 51 0.13 0.37 0.50
No. of sites under selection in Nef Frequency/distribution 53 0.12 0.39 0.50
Median OR of escape in Nef Strength/constraint 38 0.14 0.40 0.50
Median no. of covarying codons per site under selection (Gag only) Strength/constraint 26 0.084 0.68 0.81
Median OR of selection in accessory proteins Strength/constraint 45 0.059 0.70 0.81
Median OR of selection in Env Strength/constraint 32 0.067 0.72 0.81
Proportion of sites under selection in Pol (%) Frequency/distribution 51 0.0069 0.96 0.99
Median conservation of selected sites in Gag Strength/constraint 26 0.0068 0.97 0.99
Median OR of selection (proteome-wide) Strength/constraint 50 0.0024 0.99 0.99
Median conservation of selected sites in Pol Strength/constraint 39 0.0016 0.99 0.99
a Shown in boldface are q values of 0.2, indicating potential correlates of HLA-mediated protective immunity against disease progression.
Carlson et al.
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 binding via anchor residue mutation represented a major escape
mechanism and that such mutations incurred, on average, a
nearly 10-fold reduction in predicted HLA binding afﬁnity.
Among 9-mer epitopes, the statistical strength of escape muta-
tions at anchor residues was higher than for nonanchor residues.
Mutations occurring at nonanchor positions within the epitope
were less frequently detected, and those at residues immediately
ﬂankingtheNandCterminioftheepitopewerelessfrequentstill
(although still signiﬁcantly higher than in extraepitopic zones, at
least for HLA-B). Although it is tempting to conclude that abro-
gation of peptide-HLA binding represents HIV’s favored escape
mechanism, a potential limitation should be noted. It is possible
that detection of HLA-associated polymorphisms at the popula-
tion level is inherently biased toward detection of “straightfor-
ward”escapemutationssuchasthosedirectlyaffectingbindingto
HLA, while escape mutations resulting from more complex
and/or“secondary”interactions(e.g.,escapefrompopulationsof
TCRs capable of interacting with HLA-bound peptide) may be
more challenging to detect. Indeed, numerous examples exist
whereanescapevariantselectedinoneindividualishighlyrecog-
nized by another’s immune response (38, 47, 63, 90).
Despite these caveats, recent large-scale studies of immune es-
cape indicate that data sets of the present size have sufﬁcient
power to detect even rare escape mutations (26), as well as to
detect cases where escape from one HLA allele represents the sus-
ceptible form for another (19). The high frequency of anchor res-
idue escape has implications for proposed vaccine strategies
aimed at immunizing with both wild-type and common variants
to channel HIV evolution down unconventional pathways (7, 13,
19). While still valid, such strategies should consider excluding
epitope variants that are experimentally veriﬁed to not bind their
restricting HLA, unless such variants overlap key epitopes re-
stricted by other alleles and/or lead to the creation of novel
epitopes relevant to immune control (4).
Analysis of HLA-associated polymorphisms identiﬁed at the
populationlevelalsoprovidesauniqueperspectivefromwhichto
identify, albeit indirectly, speciﬁc characteristics that differentiate
protective from nonprotective HLA-restricted CTL responses.
Such sequence-based methods offer an alternative perspective to
traditionalinvitroand/orexvivoassayssuchasgammainterferon
(IFN-	) enzyme-linked immunosorbent spot (ELISpot) assays
(115), where, for a variety of reasons (including use of synthetic
consensus peptides at supraphysiological concentrations that by-
pass antigen-processing machinery, detection of a single cytokine
readout only, inability to detect previous effective responses due
to escape in the autologous virus, and others [121]), responses
detected in vitro may not accurately discriminate effective re-
sponses occurring in vivo. Indeed, a recent large-scale analysis of
2,000 chronically clade C-infected persons identiﬁed differen-
tial immune escape as a better predictor of average per-HLA
plasma viral load than responses measured by IFN-	 ELISpot as-
say (26).
Importantly, analysis of population-level HLA-associated
polymorphisms as markers of in vivo immune pressure by no
means argues that CTL escape is protective at the individual level;
indeed,escapemutationsinindividualshavebeenlinkedtohigher
viral load and disease progression (21, 26, 39, 49). At the popula-
tion level, HLA-associated polymorphic sites identify HLA-re-
strictedCTLresponsesthatareconsistentlymountedinasubstan-
tial number of individuals expressing that allele—responses that
are strong enough to drive the virus to escape in reproducible
ways. As such, these sites represent the total potential of common
CTLresponsesrestrictedbyagivenHLAalleletoeffectivelytarget
HIV; analysis of their distribution and characteristics can there-
fore help illuminate correlates of protection. Translation of these
ﬁndings to the individual level is more complex. First, not all
individuals expressing a given HLA will mount all possible CTL
responses. Broadly generalizing, from a viral control perspective,
the ideal would be to mount an effective immune response that
the virus is incapable of escaping. Less ideal (but more the norm)
wouldbetogenerateaneffectiveresponsethatthevirusultimately
is able to escape (yielding losses of immune control that in some
cases may be offset by viral ﬁtness costs). Least ideal would be the
inabilitytomounttheresponseintheﬁrstplace.Attheindividual
level,therefore,escapemutationscanberegardedasgeneticrelics
of formerly effective CTL responses, where, in general, the nega-
FIG5 Population-levelimmuneescapepathwaysinHIV-1revealcorrelatesofprotectiveimmunity:selectedresults.IndividualHLA-A,-B,and-Callelesareas
indicated. Signiﬁcant inverse correlations were observed between the total number of sites under immune selection by a given HLA across the entire HIV-1
proteome(A),themedianoddsratioofescapeinGag(B),andthepercentescapeatHLAanchorresidues(C)andpublishedhazardratiosofAIDSprogression.
HLA-B*57:01 and B*27:05 are labeled for special interest.
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 tive consequences of escape are still preferable to the inability to
mount responses at all (26).
Our proteome-wide and protein-speciﬁc analyses shed new
light on the long-standing debate around whether CTL response
breadth is (31, 101)o ri sn o t( 1) a correlate of protection. For
example, the number of Env-speciﬁc CD8 T-cell responses in
chronic infection, as measured by IFN-	 ELISpot assay, has been
associatedwithpoorerHIVcontrolattheindividuallevel(57,67),
suggesting that not all CTL responses are equally effective (29, 58,
108). Our results indicate that protective alleles (most notably
those of the HLA-A and -B loci) have the potential to exert im-
mune pressure on a larger number of sites across the viral pro-
teome and that selection breadth potential is signiﬁcantly associ-
ated with protection for all proteins except Nef (although a trend
remained for the latter). Furthermore, the number of associated
sitesacrosstheproteomeperHLAallelewastheonlyvariablethat
consistentlyemergedasanindependentcorrelateofprotectionin
multivariateanalyses.Ourobservationshighlighttheutilityofus-
ingpopulation-levelHLA-associatedpolymorphismstopreferen-
tially discriminate the impact of HLA-restricted immune re-
sponsesthataremosteffectiveatcontrollingHIV-1replicationin
vivo and suggest that the ability of an HLA allele to mount broad
CTL selection pressures to a wide variety of proteins beyond
Gag—including Env—represents a general correlate of protec-
tion.
Thenegativeresultsofthisstudyarealsoilluminating.Thelack
of correlation between HR-AIDS and the density of the amino
acidcovariationnetworkassociatedwithanygivensiteunderim-
mune selection suggests that targeting structural or functional
“network hubs” (i.e., those exhibiting higher-order evolutionary
constraintswithinagivenHIVprotein[33])isnotindependently
protective. Similarly, the lack of correlation between HR-AIDS
and average sequence conservation of sites under HLA selection
indicates that the ability to target constrained sites is not in itself
protective: it may depend on where these sites are in the HIV-1
proteome and how strongly they are targeted. Indeed, analysis at
the individual protein level revealed that the statistical strength of
selection on conserved sites (as measured by the odds ratio of
association) in Gag and, to a lesser extent, Pol but not other viral
proteins was a signiﬁcant correlate of protection. Since a high
odds ratio reﬂects both the frequency of selection among persons
expressing the HLA allele and the likelihood of reversion in per-
sons who lack the allele, it may be interpreted as an index of ex-
ceptionallystrongselectionatmutationallyconstrainedsites.Our
results thus highlight the strength of immune selection on con-
served sites within structural and functional HIV-1 proteins as an
important correlate of protection.
Gag was also conﬁrmed as a particularly effective immune tar-
get. The number of sites under active immune selection in Gag,
the number of active Gag epitopes (i.e., those harboring evidence
of immune selection), and the average number of sites under se-
lection per Gag epitope (a marker of diversity of selection pres-
sures on a given epitope) also represented signiﬁcant correlates of
protection.AlthoughanHLAallele’sabilitytoconsistentlymount
immune pressure on conserved Gag codons may appear an intui-
tive correlate of protection, the factors that constrain the virus to
escapeatthosespeciﬁcsitesremainunclear.Thatthemedianodds
ratio of escape in Gag correlated signiﬁcantly with both the num-
ber of sites under selection and the proportion of anchor residue
escape in the same protein and that in 9-mers the odds ratio of
escape was signiﬁcantly higher at anchor sites suggest that a hall-
mark of HLA-associated protection is the ability to consistently
mount intense CTL responses from which the virus is compelled
to escape (hence, the high odds of escape) but can only do so at a
limited number of positions (hence, the position speciﬁcity) and
at a biologically relevant ﬁtness cost (hence, sequence conserva-
tion in persons lacking the allele). Furthermore, if the anchor res-
idue is otherwise highly conserved, escape at this position could
indicate that CTL targeting the epitope are highly polyclonal
and/or cross-reactive, thus limiting escape options to those that
abrogateepitopepresentation.Ifso,thissupportstheclonalcom-
position and/or diversity of an epitope-speciﬁc CTL repertoire as
a correlate of protection (28, 58) and supports vaccine strategies
seeking to stimulate CTL responses to both wild-type and com-
monly occurring escape variants at nonanchor sites (11, 42, 109),
most notably in epitopes where escape at anchor residues is likely
to incur a ﬁtness cost. Indeed, a recent analysis limited to Pol
epitopes suggested that mutations which disrupt peptide binding
toprotectiveHLAalleles(particularlyHLA-Aalleles)maybehave
greater ﬁtness cost than escape from nonprotective HLA alleles
(85).
Although results provide potentially useful information to
guide future vaccine and immunogenicity studies, some limita-
tions merit mention. We employed bioinformatics and statistical
approaches to infer general mechanisms of immune evasion and
its consequences for epitope presentation in vivo, but individual
predictions will require rigorous experimental veriﬁcation prior
to consideration as potential immunogens. Furthermore, al-
thoughwell-poweredanalysesofHLA-associatedpolymorphisms
identify the majority of escape pathways commonly driven by a
given HLA (26), they may still underestimate the amount of im-
mune selection imposed on HIV at the population level. For ex-
ample, as our method detects only HIV polymorphisms whose
frequencies differ statistically among persons having or lacking a
particular HLA allele, it is unable to detect immune pressures
directed against viral codons so highly conserved that the beneﬁts
of escape would not outweigh the ﬁtness costs. The B*57-associ-
ated KF11 epitope provides a potential example of such a phe-
nomenon: when presented by B*57:01 (but not B*57:03) in con-
text of subtype B, a highly conserved, cross-reactive TCR
repertoire is induced, from which the virus escapes with great
difﬁculty (123). Furthermore, although such well-powered anal-
yses can identify extremely rare pathways (26), they may still un-
derestimate the amount of immune selection imposed on HIV at
the individual level; indeed, the extent to which unique immune
responses (and their escape pathways) occur and affect disease
progressionremainsunclear.Ourmethodmayalsopreferentially
detectstraightforwardescapepathways(suchasthosedirectlyim-
pacting peptide binding to HLA) over those that may be more
“multifactorial” and/or variable among individuals (e.g., TCR es-
cape that could occur at a variety of intraepitope positions de-
pending on the individual’s T-cell repertoire); the extent of this
potential bias could be quantiﬁed by longitudinally analyzing es-
capesitesinseroconvertercohorts(18,47,53).Movingforward,it
willbeessentialtotranslateindirectcorrelatesofprotectionatthe
HLA allele level to speciﬁc features of protective HLA-restricted
CTL responses at the individual level.
The present study conﬁrms the differential inﬂuence of HLA
classI-mediatedselectionpressuresonpopulation-levelsequence
diversity of individual HIV-1 proteins and the common occur-
Carlson et al.
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 rence of differential escape among closely related alleles (19, 24–
26,99,104).ThatthemajorityofHLA-associatedpolymorphisms
occuroutsideknownepitopessuggeststhatmanyepitopesremain
undiscovered; indeed, HLA-associated polymorphisms represent
anexcellenttooltoguideepitopediscoveryastheyareunbiasedby
consensus sequences or limited knowledge of binding motifs (5,
13, 17, 92). This study also extends our understanding of the pro-
portion of population-level HIV-1 diversity attributable to HLA
selectionpressures,identiﬁesabrogationofHLA-peptidebinding
as a predominant escape mechanism, suggests a potential evolu-
tionary mechanism underlying differential escape between allele
group members, and provides an extensive reference of pro-
teome-wide HLA-mediated escape pathways.
Importantly, our hypothesis that HLA-associated polymor-
phisms mark sites under active immune selection by HLA alleles
in vivo affords a novel perspective from which to identify features
of such responses potentially relevant to vaccine design. Speciﬁ-
cally,thetendencyforprotectiveallelestoexertselectionpressures
on a larger number of viral sites highlights selection breadth as a
general correlate of protection. The tendency of HIV-1 to evade
immune pressure by protective HLA alleles via mutations at an-
chor residues and/or at multiple sites within epitopes supports
CTLrepertoirecompositionand/ordiversityasacorrelateofpro-
tection (28, 58) although this remains controversial (82). The av-
erage sequence conservation of sites under selection was not a
general correlate of protection, indicating that the factors under-
pinning protective immune responses are more complex than
simply the ability to target conserved regions. However, that the
ability to strongly mount immune pressure on conserved sites in
Gag and Pol was protective extends the evidence supporting Gag
as a particularly effective immune target (14, 36, 67, 124) and
suggests that Gag (and Pol)-derived peptides possess characteris-
tics which render them inherently more effective as immune tar-
gets: rapid presentation of Gag-derived and, to a lesser extent,
Pol-derived peptides from incoming virions (106, 107) provides
an intriguing explanation for this phenomenon. Taken together,
our results suggest that vaccine strategies aimed at stimulating
broadCTLresponsestowardnon-Nefepitopesand,inparticular,
intensepolyclonalresponsesthatwouldforceescapeatconserved
anchor positions, especially within constrained Gag and Pol
epitopes,maybeparticularlyeffectiveatcontrollingHIV-1.Anal-
ysesofpopulation-levelescapepathwaysforotherviralpathogens
(such as hepatitis C virus) (45, 97, 118) may similarly illuminate
relevant correlates of protective cellular immunity.
ACKNOWLEDGMENTS
We gratefully acknowledge the technical, laboratory, and database
staff at the BC Centre for Excellence in HIV/AIDS in Vancouver, Can-
ada, and the Microsoft Research High Performance Computing team
in Redmond, WA.
J.M.C., C.J.B., and Z.L.B. conceived and designed the study. J.M.C.,
C.J.B., E.M., J.L., M.A.B., N.P., C.E.D, D.H., R.A., and Z.L.B. contributed
ideas, developed analytical methods, and/or performed data analysis and
interpretation. A.Q.L., C.K.S.C, L.A.C., D.J.H.F.K., and Z.L.B. collected
and/or analyzed experimental data. S.A.R., G.N., M.C., S.M., P.R.H., and
M.J. contributed cohorts and data. J.M.C. and Z.L.B. wrote the paper. All
authors critically reviewed the manuscript.
This work was supported by operating grants from the Canadian In-
stitutes for Health Research (CIHR) (MOP-93536 and HOP-115700) to
Z.L.B./M.A.B. In addition this project has been funded in part by NIAID
grants AI27670, AI36214, and AI064086 to University of California, San
Diego (UCSD; R. Haubrich) and in whole or in part with federal funds
from the Frederick National Laboratory for Cancer Research, under con-
tractnumberHHSN261200800001E.ThisResearchwassupportedinpart
by the Intramural Research Program of the NIH, Frederick National Lab,
CenterforCancerResearch.C.J.B.issupportedbyaVanierCanadaGrad-
uate Scholarship from the CIHR. E.M. is supported by a Master’s Schol-
arshipfromtheCanadianAssociationofHIVResearchandAbbottVirol-
ogy. M.A.B. holds a Canada Research Chair, Tier 2, in Viral Pathogenesis
and Immunity. J.M.C., J.L., N.P., C.E.D., and D.H. are employees of Mi-
crosoft Corporation. Z.L.B. is the recipient of a CIHR New Investigator
Award and a scholar award from the Michael Smith Foundation for
Health Research. The ACTG Human DNA Repository is supported by
grants AI068636 and RR024975. The following is a list of ACTG sites that
participated in both A5142 and A5128 protocols, along with their grant
numbers: Northwestern University (sites 2701, 2702, and 2705), Clinical
Trials Unit (CTU) grant AI 069471; University of Minnesota (sites 1501,
1504, and 1505), CTU grant AI 27661; Vanderbilt University (site 3652),
CTU grant AI-069439; Indiana University (sites 2601 and 2603), CTU
grant AI25859 and GCRC grant MO1RR000750; University of Miami
School of Medicine (site 901), CTU grant AI069477; University of Cin-
cinnati (site 2401), CTU grant AI-069513; University of Alabama (sites
5801 and 5802), CTU grant 1 U01 AI069452-01 and GCRC grant M01
RR-00032; University of Southern California (site 1201), CTU grant
AI27673; Cornell CTU (site 30329, 7803, and 7804), CTU grants
AI069419-01andCTSCRR024996;TheOhioStateUniversity(Site2301),
CTUgrantAI069474;UniversityofRochester(sites1101,1102,1107,and
1108),CTUgrantAI69411andGCRCgrant5-MO1RR00044;Univeristy
of North Carolina—Chapel Hill (site 3201), CFAR grant AI50410, CTU
grant AI69423-01, and GCRC grant RR00046; University of Pittsburgh
(site 1001 and 1008), CTU grant AI69494-01; Duke University Medical
Center(site1601),CTUgrant1U01-AI069484;Harvard/BMCCTU(sites
103, 104, and 107), CTU grant AI069472, CFAR grant AI060354, and
GCRC grant RR02635; Durban International CTU (site 11201), grant
UOIA138858; Case Western Reserve University (sites 2501, 2503, and
2508), CTU grant AI 069501; University of Pennsylvania, Philadelphia
(sites6201and6206),CTUgrantAI69467-01andCFARgrant5-P30-AI-
045008-07;ColoradoACTU(site6101),CTUgrantAI069450andGCRC
grant RR00051; University of Texas Medical Branch—Galveston (site
6301), CTU grant AI32782; Johns Hopkins University (site 201), CTU
grant AI-69465 and GCRC grant RR-00052; University of California, Los
Angeles (sites 601 and 603), CTU grant AI069424; University of Califor-
nia, Davis Medical Center (site 3852), CTU grant AI38858-09S1; Univer-
sity of Maryland, Institute of Human Virology (site 4651), CTU grant
AI069447-01; Washington University in St. Louis (site 2101), CTU grant
AI069495; University of California, San Francisco (site 801), CTU
grant AI069502-01; Stanford University (sites 501, 505, and 506), CTU
grant AI069556; University of California, San Diego (site 701), grant
AI069432; Beth Israel Medical Center (site 2851), CTU grant AI46370;
New York University/New York City Health and Hospitals Corp. at Bel-
levue Hospital Center (site 401), CTU grant AI069532 and GCRC grant
M01-RR00096; The Miriam Hospital (site 2951), CTU grant AI69472;
University of Texas Southwestern Medical Center at Dallas (site 3751),
CTU grant AI046376-05; University of Hawaii at Manoa and Queen’s
Medical Center (site 5201), CTU grant AI34853; University of Washing-
ton, Seattle (site 1401), CTU grant AI069434.
Thecontentofthispublicationdoesnotnecessarilyreﬂecttheviewsor
policiesoftheDepartmentofHealthandHumanServices,nordoesmen-
tion of trade names, commercial products, or organizations imply en-
dorsement by the U.S. Government. The funders had no role in study
design,datacollectionandanalysis,decisiontopublish,orpreparationof
the manuscript.
REFERENCES
1. Addo MM, et al. 2003. Comprehensive epitope analysis of human im-
munodeﬁciency virus type 1 (HIV-1)-speciﬁc T-cell responses directed
Lessons from Immune Escape in HIV-1
December 2012 Volume 86 Number 24 jvi.asm.org 13213
 
o
n
 
A
p
r
i
l
 
2
3
,
 
2
0
1
3
 
b
y
 
S
U
B
 
N
O
.
6
3
7
4
5
2
9
1
h
t
t
p
:
/
/
j
v
i
.
a
s
m
.
o
r
g
/
D
o
w
n
l
o
a
d
e
d
 
f
r
o
m
 against the entire expressed HIV-1 genome demonstrate broadly di-
rectedresponses,butnocorrelationtoviralload.J.Virol.77:2081–2092.
2. Akaike H. 1974. A new look at the statistical model identiﬁcation. IEEE
Trans. Automat. Contr. 19:716–723.
3. Allen TM, et al. 2005. Selective escape from CD8 T-cell responses
represents a major driving force of human immunodeﬁciency virus type
1 (HIV-1) sequence diversity and reveals constraints on HIV-1 evolu-
tion. J. Virol. 79:13239–13249.
4. Almeida CA, et al. 2011. Translation of HLA-HIV associations to the
cellularlevel:HIVadaptstoinﬂateCD8TcellresponsesagainstNefand
HLA-adapted variant epitopes. J. Immunol. 187:2502–2513.
5. Almeida CA, et al. 2010. Exploiting knowledge of immune selection in
HIV-1 to detect HIV-speciﬁc CD8 T-cell responses. Vaccine 28:6052–
6057.
6. Almeida JR, et al. 2007. Superior control of HIV-1 replication by CD8

Tcellsisreﬂectedbytheiravidity,polyfunctionality,andclonalturnover.
J. Exp. Med. 204:2473–2485.
7. Altfeld M, Allen TM. 2006. Hitting HIV where it hurts: an alternative
approach to HIV vaccine design. Trends Immunol. 27:504–510.
8. Ammaranond P, et al. 2005. A new variant cytotoxic T lymphocyte
escape mutation in HLA-B27-positive individuals infected with HIV
type 1. AIDS Res. Hum. Retroviruses 21:395–397.
9. Avila-Rios S, et al. 2009. Unique features of HLA-mediated HIV evolu-
tion in a Mexican cohort: a comparative study. Retrovirology 6:72.
10. Bansal A, et al. 2010. CD8 T cell response and evolutionary pressure to
HIV-1 cryptic epitopes derived from antisense transcription. J. Exp.
Med. 207:51–59.
11. Barouch DH, et al. 2010. Mosaic HIV-1 vaccines expand the breadth
and depth of cellular immune responses in rhesus monkeys. Nat.
Med. 16:319–323.
12. BergerCT,etal.2010.Viraladaptationtoimmuneselectionpressureby
HLA class I-restricted CTL responses targeting epitopes in HIV frame-
shift sequences. J. Exp. Med. 207:61–75.
13. Bhattacharya T, et al. 2007. Founder effects in the assessment of HIV
polymorphisms and HLA allele associations. Science 315:1583–1586.
14. Borghans JA, Molgaard A, de Boer RJ, Kesmir C. 2007. HLA alleles
associated with slow progression to AIDS truly prefer to present HIV-1
p24. PLoS One 2:e920. doi:10.1371/journal.pone.0000920.
15. Borrow P, et al. 1997. Antiviral pressure exerted by HIV-1-speciﬁc
cytotoxicTlymphocytes(CTLs)duringprimaryinfectiondemonstrated
by rapid selection of CTL escape virus. Nat. Med. 3:205–211.
16. Brackenridge S, et al. 2011. An early HIV mutation within an HLA-
B*57-restricted T cell epitope abrogates binding to the killer inhibitory
receptor 3DL1. J. Virol. 85:5415–5422.
17. Brockman MA, et al. 2012. Uncommon pathways of immune escape
attenuate HIV-1 integrase replication capacity. J. Virol. 86:6913–6923.
18. Brumme ZL, et al. 2008. Marked epitope- and allele-speciﬁc differences
in rates of mutation in human immunodeﬁciency type 1 (HIV-1) Gag,
Pol, and Nef cytotoxic T-lymphocyte epitopes in acute/early HIV-1 in-
fection. J. Virol. 82:9216–9227.
19. Brumme ZL, et al. 2007. Evidence of Differential HLA Class I-Mediated
Viral Evolution in Functional and Accessory/Regulatory Genes of
HIV-1. PLoS Pathog. 3:e94. doi:10.1371/journal.ppat.0030094.
20. Brumme ZL, et al. 2009. HLA-associated immune escape pathways in
HIV-1 subtype B Gag, Pol and Nef proteins. PLoS One 4:e6687. doi:
10.1371/journal.pone.0006687.
21. Brumme ZL, et al. 2008. Human leukocyte antigen-speciﬁc polymor-
phisms in HIV-1 Gag and their association with viral load in chronic
untreated infection. AIDS 22:1277–1286.
22. Buranapraditkun S, et al. 2011. A novel immunodominant CD8
 T cell
responserestrictedbyacommonHLA-Calleletargetsaconservedregion
of Gag HIV-1 clade CRF01_AE infected Thais. PLoS One 6:e23603. doi:
10.1371/journal.pone.0023603.
23. Cale EM, Bazick HS, Rianprakaisang TA, Alam SM, Letvin NL. 2011.
MutationsinadominantNefepitopeofsimianimmunodeﬁciencyvirus
diminish TCR:epitope peptide afﬁnity but not epitope peptide:MHC
class I binding. J. Immunol. 187:3300–3313.
24. Carlson J, Kadie C, Mallal S, Heckerman D. 2007. Leveraging hierar-
chical population structure in discrete association studies. PLoS One
2:e591. doi:10.1371/journal.pone.0000591.
25. Carlson JM, et al. 2008. Phylogenetic dependency networks: inferring
patternsofCTLescapeandcodoncovariationinHIV-1Gag.PLoSCom-
put. Biol. 4:e1000225. doi:10.1371/journal.pcbi.1000225.
26. Carlson JM, et al. 2012. Widespread impact of HLA restriction on
immune control and escape Pathways of HIV-1. J. Virol. 86:5230–5243.
27. Carrington M, O’Brien SJ. 2003. The inﬂuence of HLA genotype on
AIDS. Annu. Rev. Med. 54:535–551.
28. Chen H, et al. 2012. TCR clonotypes modulate the protective effect of
HLA class I molecules in HIV-1 infection. Nat. Immunol. 13:691–700.
29. Chen H, et al. 2009. Differential neutralization of human immunodeﬁ-
ciencyvirus(HIV)replicationinautologousCD4TcellsbyHIV-speciﬁc
cytotoxic T lymphocytes. J. Virol. 83:3138–3149.
30. Chopera DR, Wright JK, Brockman MA, Brumme ZL. 2011. Immune-
mediated attenuation of HIV-1. Future Virol. 6:917–928.
31. Chouquet C, et al. 2002. Correlation between breadth of memory HIV-
speciﬁccytotoxicTcells,viralloadanddiseaseprogressioninHIVinfec-
tion. AIDS 16:2399–2407.
32. Cotton LA, et al. 2012. HLA class I sequence-based typing using DNA
recovered from frozen plasma. J. Immunol. Methods 382:40–47.
33. Dahirel V, et al. 2011. Coordinate linkage of HIV evolution reveals
regions of immunological vulnerability. Proc. Natl. Acad. Sci. U. S. A.
108:11530–11535.
34. Dempster AP, Laird NM, Rubin DB. 1977. Maximum likelihood from
incompletedataviatheEMalgorithm.J.R.Stat.Soc.SeriesBStat.Meth-
odol. 39:1–38.
35. Draenert R, et al. 2004. Immune selection for altered antigen processing
leads to cytotoxic T lymphocyte escape in chronic HIV-1 infection. J.
Exp. Med. 199:905–915.
36. Edwards BH, et al. 2002. Magnitude of functional CD8
 T-cell re-
sponses to the gag protein of human immunodeﬁciency virus type 1
correlates inversely with viral load in plasma. J. Virol. 76:2298–2305.
37. Falk K, Rotzschke O, Stevanovic S, Jung G, Rammensee HG. 1991.
Allele-speciﬁcmotifsrevealedbysequencingofself-peptideselutedfrom
MHC molecules. Nature 351:290–296.
38. Feeney ME, et al. 2005. HIV-1 viral escape in infancy followed by emer-
gence of a variant-speciﬁc CTL response. J. Immunol. 174:7524–7530.
39. Feeney ME, et al. 2004. Immune escape precedes breakthrough human
immunodeﬁciency virus type 1 viremia and broadening of the cytotoxic
T-lymphocyte response in an HLA-B27-positive long-term-
nonprogressing child. J. Virol. 78:8927–8930.
40. FellayJ,etal.2009.CommongeneticvariationandthecontrolofHIV-1
inhumans.PLoSGenet.5:e1000791.doi:10.1371/journal.pgen.1000791.
41. Felsenstein J. 2005. PHYLIP (phylogeny inference package) version
3.6. Department of Genome Sciences, University of Washington,
Seattle, WA.
42. Fischer W, et al. 2007. Polyvalent vaccines for optimal coverage of
potential T-cell epitopes in global HIV-1 variants. Nat. Med. 13:100–
106.
43. Gao X, et al. 2001. Effect of a single amino acid change in MHC class I
moleculesontherateofprogressiontoAIDS.N.Engl.J.Med.344:1668–
1675.
44. Gaschen B, et al. 2002. Diversity considerations in HIV-1 vaccine selec-
tion. Science 296:2354–2360.
45. Gaudieri S, et al. 2006. Evidence of viral adaptation to HLA class I-re-
stricted immune pressure in chronic hepatitis C virus infection. J. Virol.
80:11094–11104.
46. Gnanakaran S, et al. 2011. Recurrent signature patterns in HIV-1 B
clade envelope glycoproteins associated with either early or chronic in-
fections. PLoS Pathog. 7:e1002209. doi:10.1371/journal.ppat.1002209.
47. Goonetilleke N, et al. 2009. The ﬁrst T cell response to transmitted/
founderviruscontributestothecontrolofacuteviremiainHIV-1infec-
tion. J. Exp. Med. 206:1253–1272.
48. Goulder PJ, et al. 2000. Differential narrow focusing of immunodomi-
nant human immunodeﬁciency virus gag-speciﬁc cytotoxic T-lympho-
cyte responses in infected African and caucasoid adults and children. J.
Virol. 74:5679–5690.
49. Goulder PJ, et al. 1997. Late escape from an immunodominant cyto-
toxic T-lymphocyte response associated with progression to AIDS. Nat.
Med. 3:212–217.
50. Goulder PJ, Watkins DI. 2004. HIV and SIV CTL escape: implications
for vaccine design. Nat. Rev. Immunol. 4:630–640.
51. Haas DW, et al. 2003. A multi-investigator/institutional DNA bank for
AIDS-relatedhumangeneticstudies:AACTGProtocolA5128.HIVClin.
Trials 4:287–300.
52. Hasan Z, et al. 2012. Minor contribution of HLA class I-associated
Carlson et al.
13214 jvi.asm.org Journal of Virology
 
o
n
 
A
p
r
i
l
 
2
3
,
 
2
0
1
3
 
b
y
 
S
U
B
 
N
O
.
6
3
7
4
5
2
9
1
h
t
t
p
:
/
/
j
v
i
.
a
s
m
.
o
r
g
/
D
o
w
n
l
o
a
d
e
d
 
f
r
o
m
 selective pressure to the variability of HIV-1 accessory protein Vpu.
Biochem. Biophys. Res. Commun. 421:291–295.
53. Henn MR, et al. 2012. Whole genome deep sequencing of HIV-1 reveals
the impact of early minor variants upon immune recognition during
acute infection. PLoS Pathog. 8:e1002529. doi:10.1371/journal.
ppat.1002529.
54. Holdsworth R, et al. 2009. The HLA dictionary 2008: a summary of
HLA-A, -B, -C, -DRB1/3/4/5, and -DQB1 alleles and their association
withserologicallydeﬁnedHLA-A,-B,-C,-DR,and-DQantigens.Tissue
Antigens 73:95–170.
55. Honeyborne I, et al. 2006. Motif inference reveals optimal CTL epitopes
presented by HLA class I alleles highly prevalent in southern Africa. J.
Immunol. 176:4699–4705.
56. Horton H, et al. 2006. Preservation of T cell proliferation restricted by
protective HLA alleles is critical for immune control of HIV-1 infection.
J. Immunol. 177:7406–7415.
57. HuangKH,etal.2011.ProgressiontoAIDSinSouthAfricaisassociated
with both reverting and compensatory viral mutations. PLoS One
6:e19018. doi:10.1371/journal.pone.0019018.
58. IglesiasMC,etal.2011.EscapefromhighlyeffectivepublicCD8
T-cell
clonotypes by HIV. Blood 118:2138–2149.
59. Iversen AK, et al. 2006. Conﬂicting selective forces affect T cell receptor
contacts in an immunodominant human immunodeﬁciency virus
epitope. Nat. Immunol. 7:179–189.
60. John M, et al. 2010. Adaptive interactions between HLA and HIV-1:
highly divergent selection imposed by HLA class I molecules with com-
mon supertype motifs. J. Immunol. 184:4368–4377.
61. Johnson VA, et al. 2011. 2011 Update of the drug resistance mutations
in HIV-1. Top. Antivir. Med. 19:156–164.
62. Kaslow RA, et al. 1996. Inﬂuence of combinations of human major
histocompatibilitycomplexgenesonthecourseofHIV-1infection.Nat.
Med. 2:405–411.
63. Kaul R, et al. 2001. CD8
 lymphocytes respond to different HIV
epitopes in seronegative and infected subjects. J. Clin. Invest. 107:1303–
1310.
64. Kawashima Y, et al. 2009. Adaptation of HIV-1 to human leukocyte
antigen class I. Nature 458:641–645.
65. Kelleher AD, et al. 2001. Clustered mutations in HIV-1 gag are consis-
tentlyrequiredforescapefromHLA-B27-restrictedcytotoxicTlympho-
cyte responses. J. Exp. Med. 193:375–386.
66. Kiepiela P, et al. 2004. Dominant inﬂuence of HLA-B in mediating the
potential co-evolution of HIV and HLA. Nature 432:769–775.
67. Kiepiela P, et al. 2007. CD8
 T-cell responses to different HIV proteins
have discordant associations with viral load. Nat. Med. 13:46–53.
68. Kloverpris HN, et al. 2012. HIV control through a single nucleotide on
the HLA-B locus. J. Virol. 86:11493–11500.
69. Kloverpris HN, et al. 2012. HLA-B*57 micropolymorphism shapes
HLA allele-speciﬁc epitope immunogenicity, selection pressure, and
HIV immune control. J. Virol. 86:919–929.
70. KosmrljA,etal.2010.EffectsofthymicselectionoftheT-cellrepertoire
onHLAclassI-associatedcontrolofHIVinfection.Nature465:350–354.
71. Koup RA. 1994. Virus escape from CTL recognition. J. Exp. Med. 180:
779–782.
72. Larder BA, Kemp SD. 1989. Multiple mutations in HIV-1 reverse trans-
criptase confer high-level resistance to zidovudine (AZT). Science 246:
1155–1158.
73. Leslie A, et al. 2005. Transmission and accumulation of CTL escape
variants drive negative associations between HIV polymorphisms and
HLA. J. Exp. Med. 201:891–902.
74. Leslie A, et al. 2006. Differential selection pressure exerted on HIV by
CTL targeting identical epitopes but restricted by distinct HLA alleles
from the same HLA supertype. J. Immunol. 177:4699–4708.
75. Listgarten J, et al. 2008. Statistical resolution of ambiguous HLA typing
data. PLoS Comput. Biol. 4:e1000016. doi:10.1371/journal.
pcbi.1000016.
76. Llano A, Frahm N, Brander C. 2009. How to optimally deﬁne optimal
cytotoxicTlymphocyteepitopesinHIVinfection,p3–24.InYusimK,et
al (ed), HIV molecular immunology. Los Alamos National Laboratory,
Los Alamos, NM.
77. Mallal SA. 1998. The Western Australian HIV Cohort Study, Perth,
Australia. J. Acquir. Immune Deﬁc. Syndr. Hum. Retrovirol. 17(Suppl
1):S23–S27.
78. MarshSGE,ParhamP,BarberLD.2000.TheHLAfactsbook.Academic
Press, London, United Kingdom.
79. Matthews PC, et al. 2011. HLA-A*7401-mediated control of HIV
viremiaisindependentofitslinkagedisequilibriumwithHLA-B*5703.J.
Immunol. 186:5675–5686.
80. Matthews PC, et al. 2009. HLA Footprints on HIV-1 are associated with
inter-clade polymorphisms and intra-clade phylogenetic clustering. J.
Virol. 83:4605–4615.
81. Matthews PC, et al. 2008. Central role of reverting mutations in HLA
associations with human immunodeﬁciency virus set point. J. Virol. 82:
8548–8559.
82. Mendoza D, et al. 2012. HLA B*5701-positive long-term nonprogres-
sors/elitecontrollersarenotdistinguishedfromprogressorsbytheclonal
composition of HIV-speciﬁc CD8
 T cells. J. Virol. 86:4014–4018.
83. Miles JJ, Douek DC, Price DA. 2011. Bias in the 
 T-cell repertoire:
implications for disease pathogenesis and vaccination. Immunol. Cell
Biol. 89:375–387.
84. Moore CB, et al. 2002. Evidence of HIV-1 adaptation to HLA-restricted
immune responses at a population level. Science 296:1439–1443.
85. Mostowy R, et al. 2012. Estimating the ﬁtness cost of escape from HLA
presentationinHIV-1proteaseandreversetranscriptase.PLoSComput.
Biol. 8:e1002525. doi:10.1371/journal.pcbi.1002525.
86. Ngumbela KC, et al. 2008. Targeting of a CD8 T cell env epitope pre-
sented by HLA-B*5802 is associated with markers of HIV disease pro-
gression and lack of selection pressure. AIDS Res. Hum. Retroviruses
24:72–82.
87. NickleDC,etal.2007.CopingwithviraldiversityinHIVvaccinedesign.
PLoS Comput. Biol. 3:e75. doi:10.1371/journal.pcbi.0030075.
88. Nielsen M, et al. 2007. NetMHCpan, a method for quantitative predic-
tions of peptide binding to any HLA-A and -B locus protein of known
sequence. PLoS One 2:e796. doi:10.1371/journal.pone.0000796.
89. O’Brien SJ, Gao X, Carrington M. 2001. HLA and AIDS: a cautionary
tale. Trends Mol. Med. 7:379–381.
90. Oxenius A, et al. 2004. Loss of viral control in early HIV-1 infection is
temporallyassociatedwithsequentialescapefromCD8
Tcellresponses
and decrease in HIV-1-speciﬁc CD4
 and CD8
 T cell frequencies. J.
Infect. Dis. 190:713–721.
91. Parker KC, et al. 1992. Sequence motifs important for peptide binding
to the human MHC class I molecule, HLA-A2. J. Immunol. 149:3580–
3587.
92. PayneRP,etal.2010.EfﬁcaciousearlyantiviralactivityofHIVGag-and
Pol-speciﬁc HLA-B 2705-restricted CD8
 T cells. J. Virol. 84:10543–
10557.
93. Pereyra F, et al. 2010. The major genetic determinants of HIV-1 control
affect HLA class I peptide presentation. Science 330:1551–1557.
94. Phillips RE, et al. 1991. Human immunodeﬁciency virus genetic varia-
tion that can escape cytotoxic T cell recognition. Nature 354:453–459.
95. PriceDA,etal.1997.PositiveselectionofHIV-1cytotoxicTlymphocyte
escape variants during primary infection. Proc. Natl. Acad. Sci. U. S. A.
94:1890–1895.
96. Price DA, et al. 2004. T cell receptor recognition motifs govern immune
escape patterns in acute SIV infection. Immunity 21:793–803.
97. RauchA,etal.2009.DivergentadaptationofhepatitisCvirusgenotypes
1 and 3 to human leukocyte antigen-restricted immune pressure. Hepa-
tology 50:1017–1029.
98. Robinson J, et al. 2011. The IMGT/HLA database. Nucleic Acids Res.
39:D1171–D1176.
99. Rolland M, et al. 2010. Amino-acid co-variation in HIV-1 Gag subtype
C: HLA-mediated selection pressure and compensatory dynamics. PLoS
One 5:e12463. doi:10.1371/journal.pone.0012463.
100. Rolland M, et al. 2011. Increased breadth and depth of cytotoxic T
lymphocytesresponsesagainstHIV-1-BNefbyinclusionofepitopevari-
ant sequences. PLoS One 6:e17969. doi:10.1371/journal.pone.0017969.
101. Rolland M, et al. 2008. Broad and Gag-biased HIV-1 epitope repertoires
are associated with lower viral loads. PLoS One 3:e1424. doi:10.1371/
journal.pone.0001424.
102. Rolland M, Nickle DC, Mullins JI. 2007. HIV-1 group M conserved
elements vaccine. PLoS Pathog. 3:e157. doi:10.1371/journal.
ppat.0030157.
103. Rolland M, et al. 2011. Genetic impact of vaccination on breakthrough
HIV-1 sequences from the STEP trial. Nat. Med. 17:366–371.
104. Rousseau CM, et al. 2008. HLA class-I driven evolution of human
Lessons from Immune Escape in HIV-1
December 2012 Volume 86 Number 24 jvi.asm.org 13215
 
o
n
 
A
p
r
i
l
 
2
3
,
 
2
0
1
3
 
b
y
 
S
U
B
 
N
O
.
6
3
7
4
5
2
9
1
h
t
t
p
:
/
/
j
v
i
.
a
s
m
.
o
r
g
/
D
o
w
n
l
o
a
d
e
d
 
f
r
o
m
 immunodeﬁciencyvirustype1subtypeCproteome:immuneescapeand
viral load. J. Virol. 82:6434–6446.
105. Sabbaj S, et al. 2003. Cross-reactive CD8
 T cell epitopes identiﬁed in
US adolescent minorities. J. Acquir. Immune Deﬁc. Syndr. 33:426–438.
106. Sacha JB, et al. 2007. Gag-speciﬁc CD8
 T lymphocytes recognize in-
fectedcellsbeforeAIDS-virusintegrationandviralproteinexpression.J.
Immunol. 178:2746–2754.
107. Sacha JB, et al. 2007. Pol-speciﬁc CD8
 T cells recognize simian immu-
nodeﬁciencyvirus-infectedcellspriortoNef-mediatedmajorhistocom-
patibility complex class I downregulation. J. Virol. 81:11703–11712.
108. Saez-Cirion A, et al. 2007. HIV controllers exhibit potent CD8 T cell
capacity to suppress HIV infection ex vivo and peculiar cytotoxic T lym-
phocyte activation phenotype. Proc. Natl. Acad. Sci. U. S. A. 104:6776–
6781.
109. Santra S, et al. 2010. Mosaic vaccines elicit CD8
 T lymphocyte re-
sponsesthatconferenhancedimmunecoverageofdiverseHIVstrainsin
monkeys. Nat. Med. 16:324–328.
110. Schuler MM, Nastke MD, Stevanovikc S. 2007. SYFPEITHI: data-
base for searching and T-cell epitope prediction. Methods Mol. Biol.
409:75–93.
111. Sidney J, Peters B, Frahm N, Brander C, Sette A. 2008. HLA class I
supertypes: a revised and updated classiﬁcation. BMC Immunol. 9:1.
doi:10.1186/1471-2172-9-1.
112. Snoeck J, Fellay J, Bartha I, Douek DC, Telenti A. 2011. Mapping of
positive selection sites in the HIV-1 genome in the context of RNA and
protein structural constraints. Retrovirology 8:87. doi:10.1186/1742-
4690-8-87.
113. Stewart-Jones GB, et al. 2005. Crystal structures and KIR3DL1 recog-
nition of three immunodominant viral peptides complexed to HLA-
B*2705. Eur. J. Immunol. 35:341–351.
114. Storey JD, Tibshirani R. 2003. Statistical signiﬁcance for genomewide
studies. Proc. Natl. Acad. Sci. U. S. A. 100:9440–9445.
115. Streeck H, Frahm N, Walker BD. 2009. The role of IFN-gamma Elispot
assay in HIV vaccine research. Nat. Protoc. 4:461–469.
116. Taylor BS, Hammer SM. 2008. The challenge of HIV-1 subtype diver-
sity. N. Engl. J. Med. 359:1965–1966.
117. Theodossis A, et al. 2010. Constraints within major histocompatibility
complex class I restricted peptides: presentation and consequences for
T-cell recognition. Proc. Natl. Acad. Sci. U. S. A. 107:5534–5539.
118. Timm J, et al. 2007. Human leukocyte antigen-associated sequence
polymorphisms in hepatitis C virus reveal reproducible immune re-
sponses and constraints on viral evolution. Hepatology 46:339–349.
119. Veerassamy S, Smith A, Tillier ER. 2003. A transition probability model
for amino acid substitutions from blocks. J. Comput. Biol. 10:997–1010.
120. Woods CK, et al. 2012. Automating HIV drug resistance genotyping
withRECall,afreelyaccessiblesequenceanalysistool.J.Clin.Microbiol.
50:1936–1942.
121. Yang OO. 2003. Will we be able to “spot” an effective HIV-1 vaccine?
Trends Immunol. 24:67–72.
122. Yokomaku Y, et al. 2004. Impaired processing and presentation of
cytotoxic-T-lymphocyte (CTL) epitopes are major escape mechanisms
from CTL immune pressure in human immunodeﬁciency virus type 1
infection. J. Virol. 78:1324–1332.
123. Yu XG, et al. 2007. Mutually exclusive T-cell receptor induction and
differential susceptibility to human immunodeﬁciency virus type 1 mu-
tational escape associated with a two-amino-acid difference between
HLA class I subtypes. J. Virol. 81:1619–1631.
124. Zuniga R, et al. 2006. Relative dominance of Gag p24-speciﬁc cytotoxic
T lymphocytes is associated with human immunodeﬁciency virus con-
trol. J. Virol. 80:3122–3125.
Carlson et al.
13216 jvi.asm.org Journal of Virology
 
o
n
 
A
p
r
i
l
 
2
3
,
 
2
0
1
3
 
b
y
 
S
U
B
 
N
O
.
6
3
7
4
5
2
9
1
h
t
t
p
:
/
/
j
v
i
.
a
s
m
.
o
r
g
/
D
o
w
n
l
o
a
d
e
d
 
f
r
o
m
 